Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins.
about
Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesSubcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.
P2860
Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Improvement of quality of life ...... subcutaneous immunoglobulins.
@en
Improvement of quality of life ...... subcutaneous immunoglobulins.
@nl
type
label
Improvement of quality of life ...... subcutaneous immunoglobulins.
@en
Improvement of quality of life ...... subcutaneous immunoglobulins.
@nl
prefLabel
Improvement of quality of life ...... subcutaneous immunoglobulins.
@en
Improvement of quality of life ...... subcutaneous immunoglobulins.
@nl
P2093
P1476
Improvement of quality of life ...... subcutaneous immunoglobulins.
@en
P2093
Dario Cocito
Emanuela Spagone
Erdita Peci
Ilaria Paolasso
P2860
P2888
P304
P356
10.1007/S10072-013-1426-5
P577
2013-04-11T00:00:00Z